Here, we describe the necessary steps for establishing a rat EVLP model and show the inflammatory profile associated with the perfused lungs. The aim is to propagate knowledge and experiences about the rat EVLP model, enabling the integral understanding of the biological responses associated with that revolutionary technique.
Since the establishment of lung transplantation as a therapeutic strategy for advanced lung diseases, the scientific community is faced with the problem of a low number of lungs considered viable for the donation process. In recent decades, however, this scenario has been positively changed, given the development of ex vivo lung perfusion (EVLP) as a strategy for evaluating and reconditioning marginal lungs. The establishment of EVLP in large transplant centers has favored an increase in the number of lung transplants, both by increasing the diagnostic accuracy of lung function and by constituting an effective platform for the reconditioning of lung grafts. In this context, faced with ethical and logistical issues, as well as in the study of immunological factors associated with lung transplantation, the development of rodent EVLP models has become important, given their reliability, the possibility of genetic manipulation, and lower costs. This paper describes a protocol for establishing a rat EVLP model and shows the inflammatory profile associated with the perfused lungs. This will help propagate knowledge about the rat EVLP model, promoting our understanding of the biological responses associated with that revolutionary technique.
Lung transplantation has been recognized as a therapeutic strategy for end-stage diseases with improvements in surgical methods and immunosuppression during the last decades. Despite the high demand, the number of acceptable deceased lung donors is lower than for other solid organs, converging to the lower number of lung transplants performed1,2,3. To address the donor pool shortage, the medical community has expanded the criteria for lung donation, turning organs previously considered nonviable into potential organs for transplantation. However, the extended criteria require different efforts for a better understanding and intervention in view of the possible systemic consequences originating from the donated organ. Ex vivo lung perfusion (EVLP) emerged as a technique that provides normothermic lung preservation, assessment of lung functions, and reconditioning of lungs previously considered unfeasible for the donation process4,5,6.
Given the growing number of lung transplants since the establishment of EVLP in large transplant centers, lung preservation and repair strategies have been increasingly investigated. In this sense, faced with ethical and logistical issues, as well as in the study of immunological factors associated with lung transplantation, the development of rodent EVLP models has become important, given their reliability, the possibility of genetic manipulation, and lower costs7,8,9. Here, we describe the necessary steps to establish a rat EVLP model and show the inflammatory profile associated with the perfused lungs.
Animal experiments were performed in compliance with the Animal Use Protocol approved by the Animal Care Committee at the University Health Network. Male Lewis rats (255-330 g) were given ad libitum access to food and water. Then, they were maintained in a controlled environment (18-22 °C) with a 12 h day-night cycle. See the Table of Materials for details related to all materials, solutions, and instruments used in this protocol.
1. Initialization of the ex vivo lung perfusion system
2. Donor lung procurement procedure
3. Ex vivo lung perfusion procedure
4. Parameters and sample management
All lungs with CIT ranging from 20 min to 18 h could be perfused for 4 h (Figure 2)13. Compliance was stable in most groups with the exception of 18 h CIT, which gradually decreased over the 4 h perfusion period (Figure 2A). Despite this, no significant differences in vascular resistance, lung graft oxygenation, and glucose levels were observed for the groups (Figure 2B-D). Lactate increased over time, was different between the groups, and tended to be higher with longer CIT (Figure 2E). Perfusate electrolytes were similar (Figure 2F-H). At the end of EVLP lung, the level of edema formation was not significantly different among groups with up to 18 h CIT; 24 h CIT led to quite severe edema13. Representative lung appearance at the end of EVLP is shown in Figure 2J. Lung tissue and perfusate inflammatory profile after 4 h of EVLP are shown in Table 213.
Figure 1: Rat ex vivo lung perfusion system design. 1, Tracheal cannula; 2, pulmonary artery cannula; 3, left atrium cannula. Please click here to view a larger version of this figure.
Figure 2: Lung function during rat EVLP protocol. (A-I) Lung function and blood gas analysis of donor lungs undergoing EVLP after exposure to different CITs. Each CIT group is depicted in a different color: 20 min (20 min-CIT) in red, 6 h (6 h-CIT) in green, 12 h (12 h-CIT) in blue, and 18 h (18 h-CIT) in black. (J) Rat donor lung appearance after 4-h EVLP in each CIT group. This figure was reproduced from Ohsumi et al.13 with permission. Abbreviations: EVLP = ex vivo lung perfusion; CIT = cold ischemic time; W/D, wet-to-dry weight. Please click here to view a larger version of this figure.
Technique | Parameters | Details | |
Perfusion | Perfusion Flow | 20% of estimated CO (estimated CO: 75 ml/kg for 250 g rats) | |
(Constant flow perfusion) | Perfusate | 150 mL of Steen solution with 1.000 USP units of sodium heparin and 50 mg of methylprednisolone | |
LA pressure | 3 cmH2O | ||
Ventilation | Inspiratory/expiratory pressure | 10/5 cmH2O | |
(Pressure control ventilation) | Respiratory rate | 40 breaths/min | |
FiO2 | Room air | ||
Recruitment maneuver | Up to 20 cmH2O - 5 min before assessment, every 30 min | ||
Deoxygenation | Mixed gas | 6% O2, 8% CO2 and balanced N2 | |
(Using a gas exchange membrane) |
Table 1: Rat EVLP perfusion strategy. Abbreviations: EVLP, ex vivo lung perfusion system; LA, left atrium; CO, cardiac output.
Cytokine/Group | 20 min - CIT (n = 4) | 6 h – CIT (n = 5) | 12 h – CIT (n = 5) | 18 h – CIT (n = 5) | P-Value | |
Interleukin-1β | ||||||
Perfusate after 4 h EVLP (pg/mL) | 4.85 ± 1.56 | 3.40 ± 2.36 | 3.55 ± 2.15 | 3.36 ± 1.67 | 0.56 | |
Lung tissue after 4 h EVLP (pg/mg) | 74.8 ± 61.6 | 110.3 ± 31.1 | 97.1 ± 61.6 | 165.2 ± 31.2 | 0.12 | |
Interleukin-6 | ||||||
Perfusate after 4h EVLP (pg/mL) | 297.1 ± 75.9 | 100.5 ± 89.2 | 247.0 ± 138.7 | 311.6 ± 237.6 | 0.11 | |
Lung tissue after 4h EVLP (pg/mg) | 9.1 ± 18.1 | 7.3 ± 16.2 | 80.2 ± 179.3 | 137.1 ± 84.9 | 0.12 |
Table 2: Inflammatory profile at the end of rat EVLP protocol. This table was adapted from Ohsumi et al.13 with permission. Data are shown as means ± SD. P values are for differences between groups by Kruskal-Wallis test with Dunn's multiple comparison test. Abbreviations: EVLP = ex vivo lung perfusion; CIT = cold ischemic time.
This study described the necessary steps for establishing a rat EVLP protocol. Here, we show that donor lungs can be perfused for 4 h after cold static preservation of up to 18 h at 4 °C. This was demonstrated by assessing lung compliance, pulmonary vascular resistance, perfusate glucose/lactate concentration, and P/F ratio.
The rise of the EVLP platform as an important tool in the evaluation of lung function and for graft reconditioning has motivated several groups to develop a rat EVLP model. These efforts are justified due to the lower cost and the possibility of biological manipulation, resulting in less sample variation, shorter experimental execution time, and wide possibilities for concept testing. Nevertheless, the establishment of reliable EVLP protocols in rats has proven to be tricky, with authors reporting difficulty in achieving stable perfusion and deterioration in lung function before 4 hours of EVLP9,11,13,14,15,16.
Addressed to these issues, researchers should be aware of possible air bubbles in the system that could favor episodes of pulmonary embolism. To do so, it needs to be ensured that the bubble trap is filled and that all connections are securely tied, preventing possible leaks. Besides this, during the development of the rat EVLP technique, the insertion of the PA and LA cannulas should be gentle, so that there is no torsion in the PA nor LA laceration, thus preventing interruption/invalidation of perfusion.
In addition to logistical factors, researchers must adhere to the perfusion protocol, as incorrect settings of the parameters can promote cyclical injuries turning perfusion unfeasible. The rat EVLP protocol described here is similar to clinical EVLP protocols, which utilize protective ventilatory and perfusion settings to avoid capillary compression by high alveolar pressure and prevent increases in pulmonary vascular resistance, as well as inflammatory markers7,13.
In conclusion, the rat EVLP model described here represents a potential tool in the study of lung grafts, allowing the evaluation in real time of the lung physiology and inflammatory changes associated with the time of perfusion, given the reproducibility and consistency of this protocol.
MC is a shareholder of Traferox Technologies Inc and consultant for Lung Bioengineering Inc. MC receives research support from Beyond Air Inc. and Synklino. The authors declare that there have been no competing interests that could have influenced the outcome reported in this paper.
Figure 1 was created with BioRender.com (confirmation of publication and licensing rights [Agreement: BT25KGSKWF]).
Name | Company | Catalog Number | Comments |
14 G intravenous catheter | BD | 381167 | Orotracheal intubation |
16 G intravenous catheter | BD | 381157 | Catheter to flush the lung |
2-0 Suture Sofsilk | Covidien | S-305 | Tracheal tube fixation |
3-0 Suture Sofsilk | Covidien | S303 | Fixation of arterial and atrial cannulas |
IPL-2 Core Isolated Perfused Lung System for Rat | Harvard Apparatus | 734276 | Ex Vivo Lung Perfusion (EVLP) system |
Ketamine (Narketan) | Vetoquinol | 440894 | Sedation/anesthesia |
Large Pulmonary Artery Cannula | Harvard Apparatus | 73-0711 | |
Left Atrial Cannula | Harvard Apparatus | 73-0712 | |
Low potassium dextran glucose solution (Perfadex) | XVIVO | 19811 | Preservation solution |
Methylprednisolone sodium succinate (SOLU-MEDROL) | Pfizer | 14705 | Anti-inflammatory |
Prostaglandin E1 (Prostin VR) | Pfizer | RX297945 | |
Small Animal Ventilator (Model 683) | Harvard Apparatus | 55-0000 | |
Sodium heparin | Leo Pharma | 453811 | |
Steen Solution | XVIVO | 19004 | Buffered extracellular solution to perfuse lungs during EVLP |
Sugita Aneur clip curv | Mizuho | 07-940-86 | Tracheal clamp |
Tracheal Cannula | Harvard Apparatus | 73-3384 | |
Xylazine (Rompun) | Bayer Healthcare | 2169592 | Sedation/anesthesia |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved